Suven Life Sciences, a biopharmaceutical company, has commenced phase-1 clinical trial in USA for SUVN-D4010, used for cognition in Alzheimer's disease.

This drug is a potent, selective, brain penetrant and orally active receptor partial agonist for the treatment of cognitive dysfunction associated with Alzheimer's disease and other dementias.

Venkat Jasti, CEO of Suven  said, ''We are very pleased that the third compound from our pipeline of molecules in CNS has moved into clinical trial that is being developed for cognitive disorders in Alzheimer's and Schizophrenia, a high unmet medical need which has huge market potential globally.''

Shares of the company gained Rs 5.6, or 2.63%, to trade at Rs 218.40. The total volume of shares traded was 78,453 at the BSE (12.36 p.m., Wednesday).